🔗 Share this article

While America undertakes historic revisions to its immunization guidelines, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by questioning Covid vaccinations throughout the pandemic and has zeroed in on possible deaths after Covid vaccination in her short time at the Food and Drug Administration.

Planned Changes to Childhood Vaccine Schedule

Agency leaders had intended to reveal major changes to the childhood vaccination calendar in December, synchronizing the US with the Danish vaccine program, according to reports – a major change that would place the US out of alignment with much of the global community with no evidence for improved outcomes. The announcement has been pushed back until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to address the audience at the meeting. She was just designated temporary leader of the FDA’s CDER, the fifth individual to head the center this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

The new acting director has repeatedly called for halting certain pediatric immunization guidelines in the US to become more similar to Denmark, a country with comprehensive healthcare and a population roughly the size of Wisconsin’s.

So far comments, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Prasad, chief of the FDA’s CBER – instead of pharmaceutical oversight.

Doubts Over Expertise

Høeg has no obvious track record in drug development, regulation or management, which has been typical for former directors of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She appears not to have any of the qualifications” for overseeing the CDER, said a neurologist and psychiatrist. “She’s never run a scientific study. She has no expertise in leading a sizeable institution. She is not an expert in industry regulation.”

Previous heads of the center would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that previous people who headed CBER have had.”

The drug center has an vast workload at the FDA, Woodcock pointed out.

“Many people just focuses on the new drug program, but the off-patent medication office approves a multitude of generic drugs. There’s a biologic copycat branch, over-the-counter program and more, and all of those need to be supervised,” Dr. Woodcock noted. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant management aspect to the role, which manages over 5,000 staff members. “It is a massive management job, if you perform it correctly,” Woodcock added.

Official Statement and Controversial Programs

Regarding questions about Dr. Høeg's fitness for the role and whether this appointment signifies greater collaboration among agency officials on immunizations, a spokesperson responded that the “concerns are based on flawed assumptions”.

“This background is consistent with the functions of her role,” the spokesperson stated, noting the time Høeg spent advising the agency head on “medication safety and approval science, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg inherits the commissioner’s new fast-track approval initiative, a disputed rapid medication authorization process that allegedly concerned her predecessors. “By what process are these therapies being picked for this voucher program? Who makes the decisions?” Dr. Howard asked. “There’s a lot of lack of transparency going on at the agency right now.”

Overall, he remarked, “the Food and Drug Administration appears to be shifting towards more relaxed oversight of most medications, except for vaccines.”

Public History on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if problematic, past, Howard observe. She released a study using unverified crowd-sourced reports to determine the rate of myocarditis after Covid vaccination. She consulted for the Florida top health official Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccines are more dangerous than they are.

Included in her “policy goals” for the new administration included revising rules for novel immunizations and halting “optional” vaccines, she said following the vote on a audio program. At the agency, Dr. Høeg has allegedly suggested preventing teenage boys from obtaining Covid vaccines.

“She is an complete dogmatist who starts off with her conclusions and reverse-engineers to accommodate the evidence in a very deceptive, untruthful manner,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|